We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go: Extended investment: Withheld
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
PCL Health is a Business-to-Business (B2B) Software-as-a-Service (SaaS) entity that aims to bring hospital-level care to anyone remotely. It asserts that the correct use of remote monitoring can reduce mortality by up to 45%. PCL Health intends to become a contender in the remote healthcare market that is set to touch $30 billion by 2023. It has developed CE rated medical-grade devices that use health algorithms combined with sensors and its proprietary range of apps to allow family members to proactively monitor the health of their loved ones, alongside carers and doctors, remotely. PCL Health has completed two pilots with 65 people and received a Letter Of Intent (LOI) from a National Health Service (NHS) Trust for a clinical trial. It won the 'Innovative Startup' competition at the 2019 Healthcare Unblocked event. PCL Health will use the investment for technology enhancement, running further pilot studies, and working capital.

Pitch Rated

51%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £394,680
The Saucy Affair Raw Sauces creates a new range of fresh, convenient, and healthy foods made of real ingredients. The company aims at relaunching 6 tried and tested products in retail, 3 dressings, and 3 sauces. The Saucy Affair Raw Sauces has targeted and engaged with 3 key revenue streams, that are: UK Retail & Wholesale, EU Food Service and Retail, and UK Food Service. With the proceeds, the company will employ an experienced team, implement its robust PR, Marketing, and Retail Activation Plan.
days to go: Expired investment: £130,724
Steve Grindrod Amplification (SGA) creates guitar amplifiers designed by Steve Grindrod, arguably one of the best electric guitar amp designers in the world. SGA already have over 50 global distributors ready to go once they have the funds for their marketing campaign. 
days to go: Expired investment: £3,300
The Juggling King (TJK) is one of the UK's first Seed-to-Bottle rum production companies from Guernsey. TJK argues that its product is the first rum ever to be distilled with cultivated sugarcane grown under glass in Guernsey and to be produced on the island. The company has appointed English former footballer Michael Owens as its global brand ambassador and featured on James Martin's Saturday Morning show. TJK has also onboarded 18 trade customers including hotels, restaurants and bars since its launch in August 2020. It will use the investment for working capital, customs & excise duty expenses, input costs, and other verticals.
days to go: Expired investment: £402,059
Helping online retailers run profitable operations by managing their orders, stock levels and couriers. Veeqo's software has been implemented in more than 300 retailers' systems and processes transactions with an average value of £16m per month. Businesses can access their data from almost any smart device and Veeqo have also released Scanner for all retailers, a hardware device with functionalities similarly used by Amazon in their distribution warehouses. Revenue is generated via retailers paying a regular licensing fee to use the Veeqo platform. This can range from £4,000 to £20,000 per annum. In addition, retailers can also lease the Veeqo Scanner from the company. Funds will allow Veeqo to develop products that can be used in-store at POS systems, as well as strengthen the business further in the UK.
days to go: Expired investment: £126,550
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph